ProCE Banner Activity

Phase I Study of Proteolysis-Targeting Chimera Degrader ARV-110 in Metastatic Castration-Resistant Prostate Cancer

Slideset Download
Conference Coverage
ARV-110, a proteolysis-targeting chimera, shows promising clinical activity in heavily pretreated mCRPC patients who have received at least 1 second-generation AR therapy.

Released: June 08, 2020

Expiration: June 07, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono